Adherence
Adherence to trial medication (pill counting) as well as overall adherence was given with 99 ± 3%. All patients in the empagliflozin group presented significant urinary glucose excretion at 1 and 3 months follow-up visits. None of the patients in the placebo group showed urinary glucose excretion (no drop-ins).